German Health Data Providers Compared: Claims Data Access, GDNG Compliance and RWE Fit for Pharma Research
Germany has one of the most analytically valuable health data environments in Europe — and one of the most structurally
Rare Disease RWE Strategy: Synthetic Control Arms, Natural History Studies and Real-World Evidence for Orphan Drug Development
Here’s a conversation I’ve had more times than I can count. A clinical development director at a rare disease biotech
Why Pharma Data Scientists Spend 70% of Their Time on Data Engineering — And How Analysis-Ready RWD Changes That
The pharmaceutical industry has reached an inflection point. Real-world evidence isn’t a nice-to-have anymore—it’s the foundation for every major strategic